Moreover, preclinical studies indicates that the attenuation of CCDC6 in lung, pleural, prostate and bladder cancer cells confer sensitivity to inhibitors of PARP1/2 [19], [20], [35], [36]. This evidence concerns the gene PARP1 and urinary bladder cancer.